Archampong T, Ojewale O, Bears K, et al. - Given a common occurrence of incomplete hepatitis B virus (HBV) suppression during antiretroviral therapy (ART) in HIV and HBV coinfected patients, researchers sought to examine if genetic factors that influence nucleoside analog pharmacokinetics affect HBV treatment response. Participants comprised 50 HIV/HBV coinfected patients who were on tenofovir disoproxil fumarate/lamivudine (TDF/3TC)-containing ART for a median (range) of 1.5 (1–7.4) years. Of these, 20 (40%) had unsuppressed HBV DNA. Negative HBe antibody, lower body mass index, and lower CD4 count at enrollment were more frequently reported for participants with unsuppressed compared with those with suppressed HBV DNA. Genotyping of selected ABCC4 single nucleotide polymorphisms (SNPs) with known effects on nucleoside pharmacokinetics revealed a novel association between ABCC4 rs11568695 SNP and poor HBV treatment response.